Mode
Text Size
Log in / Sign up
Phase 4 N=39 Randomized Treatment

The Synergistic Effect of Dexmedetomidine on Propofol for Sedation for Pediatric Endoscopy

Anesthesia

Enrolled (actual)
39
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Propofol Requirements With Pre-treatment of Dexmedetomidine With Children Who do Not Receive Dexmedetomidine. — 0.4; 0.23 mg/kg/min

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Dexmedetomidine (Drug); Propofol (Group P) (Drug); Propofol (Group DP) (Drug)
Age
Pediatric, Adult · 7+ yrs
Sex
All
Sponsor
Keira Mason
Primary completion
Sep 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Propofol Requirements With Pre-treatment of Dexmedetomidine With Children Who do Not Receive Dexmedetomidine.
0.4; 0.23
SECONDARY
Frequency of Adverse Events and the Need for Airway Interventions
0; 1
SECONDARY
Time Required to Achieve Sedation
7.5; 7
SECONDARY
Time Required to Meet Discharge Criteria From Recovery Room
63; 60
SECONDARY
Adverse Events
0; 1
SECONDARY
Number of Unplanned Airway Interventions According to the World Society of Intravenous Anaesthesia (SIVA) Adverse Sedation Event Reporting Tool
0; 1
SECONDARY
Emergence Delirium
15; 18; 1; 1
SECONDARY
Time to BIS Score
45; 50
SECONDARY
Duration of Sedation
22; 33

Summary

The primary aim of this study is to compare the propofol requirements of children who receive propofol with that of children who receive dexmedetomidine prior to propofol, for sedation for upper and lower endoscopic procedures.

Eligibility Criteria

Inclusion Criteria

  • Ages 7-18 years who are scheduled for upper or lower endoscopic procedures at Boston Children's Hospital and meets criteria to receive dexmedetomidine or propofol sedation for upper and lower endoscopic procedures
  • Provides written consent to participate in the research study
  • For females of childbearing age, pregnancy test is negative

Exclusion Criteria

  • Do not meet established sedation criteria
  • Refuses administration of study medication prior to sedation
  • History of allergy, intolerance, or reaction to dexmedetomidine or propofol or hypersensitivity
  • Current, repaired or risk of Moya-Moya disease
  • Recent stroke (cerebrovascular accident) within past 6 months
  • Uncontrolled hypertension
  • Concomitant use of opioids, beta antagonist, alpha 2 agonist or calcium channel blocker
  • Egg, soy or lecithin allergy
  • BMI greater than 30 or weight above 110th percentile
  • Refuses insertion of intravenous catheter while awake
  • Currently receiving pharmacologic agents for hypertension or cardiac disease
  • Currently receiving or has received digoxin within the past 3 months
  • Active, uncontrolled gastroesophageal reflux - an aspiration risk
  • Current (or within past 3 months) history of apnea requiring an apnea monitor
  • Unstable cardiac status (life threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction)
  • Craniofacial anomaly, which could make it difficult to effectively establish a mask airway for positive pressure ventilation if needed
  • Active, current respiratory issues that are different from the baseline status (pneumonia, exacerbation of asthma, bronchiolitis, respiratory syncytial virus)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02952222). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search